Evidence map›Paper›PMID 33806654›Full record

ReviewMolecules (Basel, Switzerland)2021

Microorganisms as a Potential Source of Molecules to Control Trypanosomatid Diseases.

Manuel Jesús Chan-Bacab, María Manuela Reyes-Estebanez, Juan Carlos Camacho-Chab, Benjamín Otto Ortega-Morales

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Saturated Iso-Type Fatty Acids from the Marine BacteriumPharmaceuticals (Basel, Switzerland) · 2024
    Article
  3. Plant Terpenoids as Hit Compounds against Trypanosomiasis.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Manuel Jesús Chan-BacabDepartamento de Microbiología Ambiental y Biotecnología, Universidad Autónoma de Campeche, Av. Agustín Melgar s/n, Campeche 24039, Mexico.ORCID 0000-0002-2292-8825
María Manuela Reyes-EstebanezDepartamento de Microbiología Ambiental y Biotecnología, Universidad Autónoma de Campeche, Av. Agustín Melgar s/n, Campeche 24039, Mexico.
Juan Carlos Camacho-ChabDepartamento de Microbiología Ambiental y Biotecnología, Universidad Autónoma de Campeche, Av. Agustín Melgar s/n, Campeche 24039, Mexico.ORCID 0000-0001-9306-2793
Benjamín Otto Ortega-MoralesDepartamento de Microbiología Ambiental y Biotecnología, Universidad Autónoma de Campeche, Av. Agustín Melgar s/n, Campeche 24039, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trypanosomatids are the causative agents of leishmaniasis and trypanosomiasis, which affect about 20 million people in the world's poorest countries, leading to 95,000 deaths per year. They are often associated with malnutrition, weak immune systems, low quality housing, and population migration. They are generally recognized as neglected tropical diseases. New drugs against these parasitic protozoa are urgently needed to counteract drug resistance, toxicity, and the high cost of commercially available drugs. Microbial bioprospecting for new molecules may play a crucial role in developing a new generation of antiparasitic drugs. This article reviews the current state of the available literature on chemically defined metabolites of microbial origin that have demonstrated antitrypanosomatid activity. In this review, bacterial and fungal metabolites are presented; they originate from a range of microorganisms, including cyanobacteria, heterotrophic bacteria, and filamentous fungi. We hope to provide a useful overview for future research to identify hits that may become the lead compounds needed to accelerate the discovery of new drugs against trypanosomatids.

Indexed as

AnimalsAntiprotozoal AgentsBacteriaFungiHumansLeishmaniasisTrypanosomatinaTrypanosomiasisAntiprotozoal Agentsantitrypanosomatid agentsleishmaniasismicrobial metabolitestrypanosomiasis

Identifiers

PMID33806654
PMCPMC7962016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.